[go: up one dir, main page]

PE20080827A1 - N-(1-hetaril-piperidin-4-il)-(het) arilamidas como moduladores del receptor ep2 - Google Patents

N-(1-hetaril-piperidin-4-il)-(het) arilamidas como moduladores del receptor ep2

Info

Publication number
PE20080827A1
PE20080827A1 PE2007001191A PE2007001191A PE20080827A1 PE 20080827 A1 PE20080827 A1 PE 20080827A1 PE 2007001191 A PE2007001191 A PE 2007001191A PE 2007001191 A PE2007001191 A PE 2007001191A PE 20080827 A1 PE20080827 A1 PE 20080827A1
Authority
PE
Peru
Prior art keywords
piperidin
quinolin
benzamide
chloro
modulators
Prior art date
Application number
PE2007001191A
Other languages
English (en)
Inventor
Nico Braeuer
Bernd Buchmann
Marcus Koppitz
Gernot Langer
Bernhard Lindenthal
Olaf Peters
Tim Wintermantel
Antonius Ter Laak
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20080827A1 publication Critical patent/PE20080827A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UN DERIVADO DE PIPERIDINAMIDA DE FORMULA (I), DONDE X E Y SON UN RADICAL NITROGENADO O UN GRUPO CH, CON LA CONDICION DE QUE AL MENOS UNO DE LOS GRUPOS X E Y SEA UN RADICAL NITROGENADO; R1 ES UN ANILLO ARILO O HETEROARILO MONO O BICICLICO DE 5 A 12 MIEMBROS OPCIONALMENTE SUSTITUIDO; R2, R3, R4 Y R5 SON H, CIANO, HALOGENO, OR6, ENTRE OTROS; R6 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C10, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-BROMO-N-[1-(7-CLORO-QUINOLIN-4-IL)-PIPERIDIN-4-IL]-BENZAMIDA, N-[1-(7-CLORO-QUINOLIN-4-IL)-PIPERIDIN-4-IL]-2-FLUORO-BENZAMIDA, N-[1-(7-CLORO-QUINOLIN-4-IL)-PIPERIDIN-4-IL]-2,4-DIFLUORO-BENZAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL RECEPTOR EP2 Y SON UTILES EN EL CONTROL DE LA FERTILIDAD, EN EL TRATAMIENTO DE LA ENDOMETRIOSIS, TRANSTORNOS MENSTRUALES, ENTRE OTROS
PE2007001191A 2006-09-07 2007-09-06 N-(1-hetaril-piperidin-4-il)-(het) arilamidas como moduladores del receptor ep2 PE20080827A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06090160A EP1903038A1 (de) 2006-09-07 2006-09-07 N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren

Publications (1)

Publication Number Publication Date
PE20080827A1 true PE20080827A1 (es) 2008-08-23

Family

ID=37660246

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001191A PE20080827A1 (es) 2006-09-07 2007-09-06 N-(1-hetaril-piperidin-4-il)-(het) arilamidas como moduladores del receptor ep2

Country Status (10)

Country Link
US (1) US20080125463A1 (es)
EP (2) EP1903038A1 (es)
JP (1) JP2010502665A (es)
AR (1) AR062696A1 (es)
CA (1) CA2662281A1 (es)
CL (1) CL2007002595A1 (es)
PE (1) PE20080827A1 (es)
TW (1) TW200819131A (es)
UY (1) UY30573A1 (es)
WO (1) WO2008028691A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2149552A1 (de) * 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) * 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
KR20130005263A (ko) 2009-12-30 2013-01-15 아르퀼 인코포레이티드 치환된 나프탈레닐-피리미딘 화합물
WO2011113512A1 (de) * 2010-03-16 2011-09-22 Merck Patent Gmbh Morpholinylchinazoline
PL2621923T3 (pl) 2010-09-29 2017-08-31 Intervet International B.V. Związki n-heteroarylu z mostkami cyklicznymi do leczenia chorób pasożytniczych
CN103189356B (zh) 2010-09-29 2015-11-25 英特维特国际股份有限公司 N-杂芳基化合物
JP5935154B2 (ja) * 2011-03-14 2016-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ１１９モジュレーターとしてのｎ−シクロプロピル−ｎ−ピペリジニルベンズアミド
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
EP2831042B1 (en) 2012-03-28 2019-07-31 Intervet International B.V. Heteroaryl compounds with a-cyclic bridging unit
AU2013241854B2 (en) 2012-03-28 2017-11-02 Intervet International B.V. Heteroaryl compounds with cyclic bridging unit for use in the treatment helminth infection
RU2638540C1 (ru) 2012-04-24 2017-12-14 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы днк-пк
EP2970218B8 (en) 2013-03-12 2019-04-10 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
ES2705342T3 (es) 2013-10-17 2019-03-22 Vertex Pharma Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK
MA41168A (fr) * 2014-12-17 2017-10-24 Acraf Nouveaux composés antibactériens
CN107849022A (zh) 2015-04-10 2018-03-27 亚瑞克西斯制药公司 取代的喹唑啉化合物和其使用方法
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EA038635B9 (ru) 2015-11-16 2021-10-26 Араксис Фарма Ллк 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
JP6882299B2 (ja) * 2015-12-17 2021-06-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用
US10947214B2 (en) 2016-08-08 2021-03-16 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
TW201815418A (zh) 2016-09-27 2018-05-01 Vertex Pharma 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US11059819B2 (en) 2017-01-26 2021-07-13 Janssen Biotech, Inc. Fused hetero-hetero bicyclic compounds and methods of use thereof
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
WO2018218070A2 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras
WO2020028706A1 (en) 2018-08-01 2020-02-06 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1460389A (en) * 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
JPH11171774A (ja) * 1997-12-05 1999-06-29 Kyowa Hakko Kogyo Co Ltd 血球増多剤
AU3344099A (en) * 1998-04-17 1999-11-08 Kyowa Hakko Kogyo Co. Ltd. Analgetic agent
WO2002009717A1 (fr) * 2000-07-31 2002-02-07 Ono Pharmaceutical Co., Ltd. Remedes contre la dyserection contenant des derives de prostaglandine comme principe actif
JP4310109B2 (ja) * 2001-04-26 2009-08-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
TW200526626A (en) * 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
US20060019975A1 (en) * 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline

Also Published As

Publication number Publication date
TW200819131A (en) 2008-05-01
CL2007002595A1 (es) 2008-04-18
UY30573A1 (es) 2008-05-02
CA2662281A1 (en) 2008-03-13
WO2008028691A1 (en) 2008-03-13
JP2010502665A (ja) 2010-01-28
US20080125463A1 (en) 2008-05-29
AR062696A1 (es) 2008-11-26
EP1903038A1 (de) 2008-03-26
EP2066654A1 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
PE20080827A1 (es) N-(1-hetaril-piperidin-4-il)-(het) arilamidas como moduladores del receptor ep2
CL2011002016A1 (es) Compuestos derivados de benzimidazol con actividad inhibidora de la funcion de la proteina ns5a codificada por el virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; utiles en el tratamiento de una infeccion por el virus de la hepatitis c (vhc).
MX2007014400A (es) Novedosos compuestos heterociclicos como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
ECSP109958A (es) Derivados de pirimidina 934
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
AR059977A1 (es) Compuesto de ciclohexil piperidinil dihidrobenzimidazol composicion farmaceutica que lo comprende su uso para la preparacion de un medicamento proceso para preparalo y compuesto intermediario para la sintesis del mismo
PE20110397A1 (es) Compuestos que modulan selectivamente el receptor cb2
SE0303180D0 (sv) Novel compounds
RS39704A (sr) Novi 1,2,4-tiadiazolijum derivati kao modulatori melanokortinskog receptora
SE0201635D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
ATE411323T1 (de) Cgrp-rezeptorantagonisten
UY29346A1 (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
ES2561425T3 (es) (Aza)ciclohexanos carbonilados como ligandos de receptor D3 de la dopamina
WO2008056259A3 (en) Oxazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
ATE466860T1 (de) Cgrp-rezeptorantagonisten
DE602006014305D1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
PE20221083A1 (es) Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
DE602006017209D1 (de) Carbamat-derivate als positive allosterische modulatoren von metabotropischen glutamat-rezeptoren
EA201000316A1 (ru) Производные изохинолинила и изоиндолинила в качестве антагонистов гистаминовых рецепторов 3 подтипа
ATE486071T1 (de) Azabicycloä3.1.0ühexan-derivate als modulatoren des dopamin-d3-rezeptors
ATE466853T1 (de) Cgrp-rezeptorantagonisten
AR072189A1 (es) Derivados heterociclicos de benzo[b][1,4] oxazinonas moduladores de adrenoreceptores beta 2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de enfermedades del aparato respiratorio.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal